AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
RENO, NEV. -- First-trimester nuchal translucency measurement proved to be a "reasonably sensitive" means of identifying aneuploidy in high-risk patients in a metaanalysis presented at the annual meeting of the Society for Maternal-Fetal Medicine.
In a poster session, Dr. Ellen Mozurkewich analyzed 27 studies including 163,450 subjects and reported that nuchal translucency measurements identified 78% of fetuses affected by trisomy 21, 82% of those with trisomy 18, 90% of those with trisomy 13, and 96% of those with monosomy X.
The negative predictive value for all four conditions was 99%. The false-positive rate for each of the conditions was less than 5%.
The current standard of care in the United States is for women aged 35 and older to be offered amniocentesis or chorionic villi sampling to screen for aneuploidy, but many women decline the invasive testing or request second-trimester ultrasound or biochemical screening before making a decision on invasive testing, said Dr. Mozurkewich of the University of Michigan, Ann Arbor. ...